Effect of pre-ovulatory single dose GnRH agonist therapy on IVF outcome in GnRH antagonist cycles; A prospective study

Journal of Reproduction and Infertility

Volumn 13, Issue 4, 2012, Pages 225-231

  Kaur, Harpreet ^a   Krishna, Deepika ^a   Shetty, Nivedita ^a   Krishnan, Sandhya ^a   Srinivas, M S ^a   Rao, Kamini A ^a  

^a Bangalore Assisted Conception Centre   (India)

Author keywords

Antagonist; GnRH; IVF; Ovulation; Pregnancy outcome; Trigger

Indexed keywords

CHORIONIC GONADOTROPIN; ESTRADIOL; GANIRELIX; LUTEINIZING HORMONE; OVUMAX; PROGESTERONE; TRIPTORELIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL DIVISION; CONTROLLED STUDY; FEMALE; FERTILIZATION; FERTILIZATION IN VITRO; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; OOCYTE MATURATION; OOCYTE RETRIEVAL; OUTCOME ASSESSMENT; OVULATION; PREGNANCY OUTCOME; PREGNANCY RATE; PROSPECTIVE STUDY;

EID: 84872585059     PISSN: 22285482     EISSN: 2251676X     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Fleming R, Adam AH, Barlow DH, Black WP, Mac Naughton MC, Coutts Jr. A new systematic treatment for infertile women with abnormal hormone profiles. Br J Obstet Gynaecol. 1982;89(1):80-3.
2. Ludwig M. Text book of Assisted Reproductive Technologies. 3rd ed. London: Informa healthcare UK Ltd; 2009. p. 539.
3. Schachter M, Friedler S, Ron-El R, Zimmerman AL, Strassburger D, Bern O, et al. Can pregnancy rate be improved in gonadotropin-releasing hormone (Gn RH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective, randomized study. Fertil Steril. 2008;90(4):1087-93.
4. Griesinger G, Diedrich K, Tarlatzis BC, Kolibianakis EM. GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis. Reprod Biomed Online. 2006;13(5):628-38.
5. Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev. 2006;(3):CD001750.
6. Kolibianakis EM, Collins J, Tarlatzis BC, Devroey P, Diedrich K, Griesinger G. Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and metaanalysis. Hum Reprod Update. 2006;12(6):651-71.
7. Zikopoulos K, Kolibianakis EM, Camus M, Tournaye H, Van den Abbeel E, Joris H, et al. Duration of gonadotropin-releasing hormone antagonist administration does not affect the outcome of subsequent frozen-thawed cycles. Fertil Steril. 2004;81 (2):473-5.
8. Kol S, Lightman A, Hillensjo T, Devroey P, Fauser B, Tarlatzis B, et al. High doses of gonadotrophinreleasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles. Hum Reprod. 1999;14(9): 2242-4.
9. Yu B, Ruman J, Christman G. The role of peripheral gonadotropin-releasing hormone receptors in female reproduction. Fertil Steril. 2011;95(2):465-73.
10. Pirard C, Donnez J, Loumaye E. GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study. Hum Reprod. 2006;21(7):1894-900.
11. Tesarik J, Hazout A, Mendoza-Tesarik R, Mendoza N, Mendoza C. Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles. Hum Reprod. 2006;21(10):2572-9.
12. Lin YC, Chang SY, Lan KC, Huang HW, Chang CY, Tsai MY, et al. Human oocyte maturity in vivo determines the outcome of blastocyst development in vitro. J Assist Reprod Genet. 2003;20(12): 506-12.
13. Veek LL. An Atlas of human gametes and conceptuses. 1st ed. London. Parthenon; 1999. p. 215.
14. Youssef MA, Van der Veen F, Al-Inany HG, Griesinger G, Mochtar MH, van Wely M. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles. Cochrane Database Syst Rev. 2010;(11):CD008046.
15. Hernandez ER. Embryo implantation and GnRH antagonists: embryo implantation: the Rubicon for GnRH antagonists. Hum Reprod. 2000;15(6):1211-6.
16. Raga F, Casañ EM, Kruessel J, Wen Y, Bonilla-Musoles F, Polan ML. The role of gonadotropinreleasing hormone in murine preimplantation embryonic development. Endocrinology. 1999;140(8): 3705-12.
17. Rackow BW, Kliman HJ, Taylor HS. GnRH antagonists may affect endometrial receptivity. Fertil Steril. 2008;89(5):1234-9.
18. Tesarik J, Hazout A, Mendoza C. Enhancement of embryo developmental potential by a single administration of GnRH agonist at the time of implantation. Hum Reprod. 2004;19(5):1176-80.
19. Isik AZ, Caglar GS, Sozen E, Akarsu C, Tuncay G, Ozbicer T, et al. Single-dose GnRH agonist administration in the luteal phase of GnRH antagonist cycles: a prospective randomized study. Reprod Biomed Online. 2009;19(4):472-7.
20. Ata B, Urman B. Single dose GnRH agonist administration in the luteal phase of assisted reproduction cycles: is the effect dependent on the type of GnRH analogue used for pituitary suppression? Reprod Biomed Online. 2010;20(1):165-6.